FibroGen EPS misses by $0.38, misses on revenue

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

FibroGen EPS misses by $0.38, misses on revenue

To read the full story on Seeking Alpha, click here.

FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more FibroGen Charts.

FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more FibroGen Charts.

FibroGen Inc News

FibroGen to Report First Quarter 2024 Financial Results
Monday 29 April 2024 (3 days ago) • GlobeNewswire Inc.

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A
Thursday 25 April 2024 (1 week ago) • GlobeNewswire Inc.

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)

More FibroGen Inc News Articles

Verizon Communications

Woodside Petroleum

Australian SE All Ordina...

Invesco QQQ Trust Series 1

Westpac Banking

Commonwealth Bank Of Aus...

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions